Holen Sie sich die Stockscreener-App
16.59
6.38%
-1.051
Schlusskurs vom Vortag:
$17.64
Offen:
$17.54
24-Stunden-Volumen:
59,417
Relative Volume:
0.43
Marktkapitalisierung:
$722.43M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
-3.20%
1M Leistung:
+59.86%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
1-Tages-Spanne:
$16.11
$18.40
1-Wochen-Bereich:
$15.17
$18.67
52-Wochen-Spanne:
$6.71
$18.67
Maze Therapeutics Inc Stock (MAZE) Company Profile
Firmenname
Maze Therapeutics Inc
Sektor
Branche
Telefon
(650) 850-5070
Adresse
171 OYSTER POINT BOULEVARD, SUITE 300, SOUTH SAN FRANCISCO
Vergleichen Sie MAZE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MAZE
Maze Therapeutics Inc
|
16.50 | 741.92M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
475.19 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
571.92 | 60.56B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
331.46 | 42.41B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
588.61 | 34.96B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
296.06 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Maze Therapeutics Inc Stock (MAZE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-08 | Eingeleitet | Wedbush | Outperform |
Maze Therapeutics Inc Aktie (MAZE) Neueste Nachrichten
Maze Therapeutics Inc. Stock Analysis and ForecastTremendous wealth creation - Autocar Professional
What drives Maze Therapeutics Inc. stock priceExceptional market positioning - jammulinksnews.com
This Celsius Holdings Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga
H.C. Wainwright initiates coverage on Maze Therapeutics stock with Buy rating - Investing.com UK
What analysts say about Maze Therapeutics Inc. stockExceptional growth trajectory - jammulinksnews.com
Maze Therapeutics, Inc.: Buy Rating Initiated on Precision Nephrology Potential and Undervalued Stock - TipRanks
Is Maze Therapeutics Inc. a good long term investmentHigh-velocity gains - Autocar Professional
Maze Therapeutics, Inc.’s (NASDAQ:MAZE) Lock-Up Period To Expire on July 30th - Defense World
What makes Maze Therapeutics Inc. stock price move sharplySecure Your Capital Strategy - Newser
Why Maze Therapeutics Inc. stock attracts strong analyst attentionFree Capital Growth Strategies - Newser
how maze therapeutics inc. stock performs during market volatilityDaily Trade Opportunity - Newser
How Maze Therapeutics Inc. stock performs during market volatilityDaily Gain Forecast - Newser
Maze Therapeutics (NASDAQ:MAZE) Research Coverage Started at Wedbush - Defense World
Q2 Earnings Estimate for Maze Therapeutics Issued By Wedbush - Defense World
Brokerages Set Maze Therapeutics, Inc. (NASDAQ:MAZE) Target Price at $23.50 - Defense World
Maze Therapeutics to Participate in Two Upcoming Investor Conferences - GlobeNewswire
Maze Therapeutics Showcases Precision Medicine Pipeline at Major Kidney and Biotech Investor Conferences - Stock Titan
Maze Therapeutics Soars 11.68% on Wedbush's Outperform Rating - AInvest
Maze Therapeutics' Development Strategy Using Genetic Validation Seen as Promising, Wedbush Says - MarketScreener
Maze Therapeutics to Participate in the Jefferies 2025 Global Healthcare Conference - GlobeNewswire
Pre-market Movers: SPRO, ASBP, IFRX, IMNN... - RTTNews
Analysts Offer Insights on Healthcare Companies: Strata Skin Sciences (SSKN), Ionis Pharmaceuticals (IONS) and Maze Therapeutics, Inc. (MAZE) - The Globe and Mail
Positive Outlook for Maze Therapeutics: Buy Rating Reiterated Amid Promising Drug Developments and Strong Financial Position - TipRanks
Comparing DBV Technologies (NASDAQ:DBVT) and Maze Therapeutics (NASDAQ:MAZE) - Defense World
Contrasting Repligen (NASDAQ:RGEN) & Maze Therapeutics (NASDAQ:MAZE) - Defense World
Maze Therapeutics Reports First Quarter 2025 Financial Results and Reiterates Upcoming Milestones - GlobeNewswire
Maze Therapeutics Q1 Earnings: Dual Clinical Programs Progress as Cash Position Hits $294M - Stock Titan
Maze Therapeutics to Participate in the 3rd Annual H.C. Wainwright BioConnect Investor Conference - The Manila Times
Maze Therapeutics CEO to Present Company Overview at 3rd Annual H.C. Wainwright BioConnect Investor Conference - Nasdaq
Finanzdaten der Maze Therapeutics Inc-Aktie (MAZE)
Es liegen keine Finanzdaten für Maze Therapeutics Inc (MAZE) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
3.26%
0.14%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):